Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationCurrent Price
as of Oct 16, 2024$0.81
P/E Ratio
N/A
Market Cap
$185.32M
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in March 2004 and is headquartered in South San Francisco, CA.
Overview
Trading Information
Company